Oncimmune granted funding for Covid-19 research collaboration
6th Oct 2020 13:54
(Sharecast News) - Immunodiagnostics company Oncimmune Holdings announced the award of funding from UK Research and Innovation's (UKRI) 'Ideas to Address Covid-19' programme on Tuesday.
Read moreOncimmune enters collaboration with Roche subsidiary
23rd Sep 2020 16:05
(Sharecast News) - Immunodiagnostics group Oncimmune Holdings has signed a collaboration with Roche subsidiary Genentech, it announced on Wednesday, to characterise the autoantibody profiles of patients in clinical trials for rheumatological diseases, including systemic lupus erythematosus (SLE).
Read moreOncimmune announces autoantibody profiling collaboration
2nd Sep 2020 13:49
(Sharecast News) - Immunodiagnostics company Oncimmune Holdings has signed an autoantibody profiling collaboration with an unnamed "leading global biopharmaceutical company", it announced on Wednesday, which it said had "extensive experience" in developing novel immune checkpoint inhibitors (CPIs).
Read moreRoche extends scope and value of contract with Oncimmune
27th Jul 2020 09:22
(Sharecast News) - Immunodiagnostics company Oncimmune Holdings announced on Monday that Roche has exercised its option to increase the scope and value of the cornerstone contract, initially announced on 28 May.
Read moreOncimmune expects to report further strong top-line growth
4th Jun 2020 10:50
(Sharecast News) - Immunodiagnostics group Oncimmune Holdings said on Thursday that it expects to report further strong top-line growth in its current trading year.
Read moreOncimmune signs collaboration deal with US biopharma company
12th May 2020 15:32
(Sharecast News) - Immunodiagnostics company Oncimmune Holdings has signed an antigen-targeting collaboration, it announced on Tuesday, to support drug development with a "leading", unnamed United States biopharmaceutical company, which is developing novel therapies based on the human immune response.
Read moreOncimmune funded into 2021 with new EUR 8.5m facility
20th Sep 2019 15:47
(Sharecast News) - Immunodiagnostics company Oncimmune Holdings has secured a credit facility of €8.5m (£7.5m) with IPF Management, it announced on Friday.
Read moreOncimmune sells US operations to and partners with Biodesix
28th Jun 2019 11:03
(Sharecast News) - Immunodiagnostics company Oncimmune Holdings has entered into an exclusive partnership agreement, it announced on Friday, which it said could "unlock the full potential" of its 'EarlyCDT Lung' product in the United States.
Read moreOncimmune confident of 'material profitable revenues'
26th Jun 2019 10:58
(Sharecast News) - Immunodiagnostics firm Oncimmune told investors on Wednesday it was confident it could generate "material profitable revenues" on the back of several business developments.
Read moreOncimmune distributor gets approval for 'EarlyCDT-Lung' in Israel
15th May 2019 15:27
(Sharecast News) - Immunodiagnostics company Oncimmune Holdings announced on Wednesday that its distributor for Israel, Best Medical Opinion, has received regulatory approval for the sale of the 'EarlyCDT-Lung' product in Israel.
Read moreOncimmune begins study to bring 'EarlyCDT-Lung' to China
10th May 2019 12:59
(Sharecast News) - Oncimmune Holdings, alongside its partner Genostics Company, announced the start of a multi-centre case control study on early lung cancer detection for screening and nodules in the People's Republic of China on Friday, using an extended panel of autoantibodies to accommodate variations in the biomarkers expressed on cancer cells in Asian populations.
Read moreOncimmune inks distribution deal for lung cancer test in Portugal
5th Apr 2019 15:10
(Sharecast News) - Personalised immunodiagnostics developer Oncimmune Holdings has signed an exclusive agreement for the distribution of its 'EarlyCDT-Lung' test kit in Portugal with Sabartech, its existing distributor in Spain, it announced on Friday.
Read moreOncimmune strengthens scientific board with addition of Parag Mallick
2nd Apr 2019 10:50
(Sharecast News) - Immunodiagnostics company Oncimmune Holdings announced the appointment of Dr Parag Mallick - an associate professor of radiology at Stanford University - to its scientific board on Tuesday.
Read moreOncimmune acquires Protagen Diagnostics in £4.11m deal
19th Mar 2019 09:10
(Sharecast News) - Oncimmune Holdings has acquired Protagen Diagnostics for a total consideration of up to £4.11m, it announced on Tuesday, to be paid by the allotment of up to 2,635,910 Oncimmune ordinary shares at 156p each 0 a premium of 71% to the closing mid-market price on 18 March.
Read moreOncimmune Holdings' loss deepens on spiralling costs
13th Feb 2019 09:20
(Sharecast News) - Oncimmune Holdings reported a widened interim loss on Wednesday as increases to research & development costs and administrative costs outweighed a rise in revenue.
Read more